As part of the deal, users will be able to integrate Roche’s Accu-Chek Insights insulin pump with the Diabeloop monitoring system.
Typically, hybrid systems are made up of a continuous glucose monitor, an insulin pump, and a glucose-detecting algorithm.
The Diabeloop system uses an algorithm to continuously monitor insulin levels and data.
In 2018, the Lancet published an investigative study that found the hybrid closed-loop demonstrated improved glucose control and lower risk of hypoglycemia compared to those managing their glucose levels with an insulin pump and CGM. “Diabetes management is complex and personal, and achieving therapy goals is an ongoing challenge. The integration of the Accu-Chek Insight insulin pump into an AID system creates new opportunities to lower the burden of constant insulin dose adjustment for people with diabetes,” Marcel Gmuender, head of Roche Diabetes Care, said in a statement.
Medtronic’s MiniMed 770G System landed FDA clearance in 2020 for its hybrid closed-loop system, which marked the first time an automated insulin-delivery system was greenlighted for young children with Type 1 diabetes.
Read full article here
